Revenue
2020
2021
2022
2023
2024
2025
Carvolix (AFME)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | €0 | €4.1M | €0 | €0 | €0 | €0 |
| Operating income | −€23.7M | −€14.6M | −€15.4M | −€14.3M | −€13.2M | −€13.0M |
| Operating margin | — | −355.49% | — | — | — | — |
| EBITDA | −€17.1M | −€12.2M | −€13.0M | −€11.8M | −€10.8M | −€11.1M |
| EBITDA margin | — | −297.30% | — | — | — | — |
| Net income | −€25.0M | −€14.7M | −€15.7M | −€15.2M | −€14.8M | −€14.3M |
| Net profit margin | — | −357.92% | — | — | — | — |
| Basic EPSper basic share | -€0.63 | -€0.41 | -€0.54 | -€0.81 | -€0.88 | -€1.07 |
| Diluted EPSper diluted share | -€0.63 | -€0.41 | -€0.54 | -€0.81 | -€0.88 | -€1.07 |
Owners
Reported shareholders and owner groups
68.98%of company shares
Truffle CapitalSource updated Oct 16, 2026
View holders
| Holder | Ownership |
|---|---|
Truffle Capital | 68.98%Oct 16, 2026 |
Edwards Lifesciences Research Holding LLC | 9.72%Oct 16, 2026 |
Financière Memnon | 6.91%Oct 16, 2026 |
Employees | 0.04%Oct 16, 2026 |
Managers and Members of the board | 0.03%Oct 16, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026